Literature DB >> 32115905

Mandatory newborn screening in the United States: History, current status, and existential challenges.

Shawn E McCandless1, Erica J Wright1.   

Abstract

Beginning in the 1960s, mandatory newborn screening (NBS) of essentially all infants has been a major public health success story. NBS is not just a blood test, rather, it is a complex, integrated system that begins with timely testing, scrupulous follow up of patients, tracking of outcomes, quality improvement of all aspects of the process, and education of providers, staff, and parents. In the past, expansion of NBS programs has been driven by new testing technology, but now is increasingly driven by the development of novel therapeutics and political advocacy. Each state determines how the NBS system will be structured in that state, but there is increasing oversight and support for harmonization at a federal level. Several recent initiatives, together with the increased number of conditions screened and the concomitant increase in burdensome false-positive tests, are creating new scrutiny of NBS systems, and potentially pose an existential risk to the public acceptance of mandatory NBS. The history, current state and challenges for NBS are explored in this issue, with some suggestions as to how to address them.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  CF; MS/MS; PKU; cystic fibrosis; intellectual disability; population-based health screening; presymptomatic; prevention; public health; recommended uniform screening panel (RUSP)

Year:  2020        PMID: 32115905     DOI: 10.1002/bdr2.1653

Source DB:  PubMed          Journal:  Birth Defects Res            Impact factor:   2.344


  10 in total

1.  Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.

Authors:  Kevin A Strauss; Michelle A Farrar; Francesco Muntoni; Kayoko Saito; Jerry R Mendell; Laurent Servais; Hugh J McMillan; Richard S Finkel; Kathryn J Swoboda; Jennifer M Kwon; Craig M Zaidman; Claudia A Chiriboga; Susan T Iannaccone; Jena M Krueger; Julie A Parsons; Perry B Shieh; Sarah Kavanagh; Sitra Tauscher-Wisniewski; Bryan E McGill; Thomas A Macek
Journal:  Nat Med       Date:  2022-06-17       Impact factor: 87.241

2.  Exome/Genome-Wide Testing in Newborn Screening: A Proportionate Path Forward.

Authors:  Vasiliki Rahimzadeh; Jan M Friedman; Guido de Wert; Bartha M Knoppers
Journal:  Front Genet       Date:  2022-07-04       Impact factor: 4.772

3.  Genetic spectrum and clinical early natural history of glucose-6-phosphate dehydrogenase deficiency in Mexican children detected through newborn screening.

Authors:  Marcela Vela-Amieva; Miguel Angel Alcántara-Ortigoza; Ariadna González-Del Angel; Leticia Belmont-Martínez; Carlos López-Candiani; Isabel Ibarra-González
Journal:  Orphanet J Rare Dis       Date:  2021-02-26       Impact factor: 4.123

4.  Expert Evaluation of Strategies to Modernize Newborn Screening in the United States.

Authors:  Donald B Bailey; Katherine Ackerman Porter; Sara M Andrews; Melissa Raspa; Angela Y Gwaltney; Holly L Peay
Journal:  JAMA Netw Open       Date:  2021-12-01

Review 5.  Newborn Screening: Review of its Impact for Cystinosis.

Authors:  Katharina Hohenfellner; Ewa Elenberg; Gema Ariceta; Galina Nesterova; Neveen A Soliman; Rezan Topaloglu
Journal:  Cells       Date:  2022-03-25       Impact factor: 6.600

6.  Pain points in parents' interactions with newborn screening systems: a qualitative study.

Authors:  Mike Conway; Truc Thuy Vuong; Kim Hart; Andreas Rohrwasser; Karen Eilbeck
Journal:  BMC Pediatr       Date:  2022-03-31       Impact factor: 2.125

7.  A Window of Opportunity for Newborn Screening.

Authors:  Donald B Bailey
Journal:  Mol Diagn Ther       Date:  2022-05-04       Impact factor: 4.476

Review 8.  Population-based screening of newborns: Findings from the newborn screening expansion study (part two).

Authors:  Kee Chan; Amy Brower; Marc S Williams
Journal:  Front Genet       Date:  2022-09-01       Impact factor: 4.772

Review 9.  The Use of Whole Genome and Exome Sequencing for Newborn Screening: Challenges and Opportunities for Population Health.

Authors:  Audrey C Woerner; Renata C Gallagher; Jerry Vockley; Aashish N Adhikari
Journal:  Front Pediatr       Date:  2021-07-19       Impact factor: 3.418

10.  PRDX1 gene-related epi-cblC disease is a common type of inborn error of cobalamin metabolism with mono- or bi-allelic MMACHC epimutations.

Authors:  Catia Cavicchi; Abderrahim Oussalah; Silvia Falliano; Lorenzo Ferri; Alessia Gozzini; Serena Gasperini; Serena Motta; Miriam Rigoldi; Giancarlo Parenti; Albina Tummolo; Concetta Meli; Francesca Menni; Francesca Furlan; Marta Daniotti; Sabrina Malvagia; Giancarlo la Marca; Céline Chery; Pierre-Emmanuel Morange; David Tregouet; Maria Alice Donati; Renzo Guerrini; Jean-Louis Guéant; Amelia Morrone
Journal:  Clin Epigenetics       Date:  2021-07-02       Impact factor: 6.551

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.